1型糖尿病功能性治愈

Search documents
Latest breakthrough in Type 1 diabetes treatment: Chinese medical team enables 24 patients to discontinue insulin use
Globenewswire· 2025-08-21 01:11
Core Insights - A groundbreaking achievement in treating Type 1 diabetes mellitus (T1DM) has been reported by Professor An Chiying and her team at Shenzhen Hengsheng Hospital, where 24 patients have successfully discontinued insulin therapy through holistic integrative medicine (HIM) since June 2024, with the longest insulin-free duration reaching 14 months [1][5] Group 1: Treatment Methodology - The HIM model combines traditional Chinese medicine (TCM), orthomolecular medicine, functional medicine, and lifestyle medicine, focusing on immune blockade and metabolic balance, alongside precision remote digital healthcare to restore islet function [2][3] - The treatment protocol involves multidisciplinary collaboration, including precision diagnostics, immune regulation through molecular nutrition and TCM, metabolic repair via acupuncture and herbal medicine, and precision monitoring using artificial intelligence for personalized treatment adjustments [3] Group 2: Clinical Outcomes - Over a two-year observation period, 70 T1DM patients were treated, with 24 patients (34%) completely discontinuing insulin use while maintaining stable blood glucose levels (HbA1c < 7%) and showing significant recovery of islet function as indicated by C-peptide testing [5][6] - Patients diagnosed early with T1DM and having a C-peptide level above 0.5 ng/ml can stop insulin, while those with lower islet function can significantly reduce insulin dosage once blood glucose levels are stabilized [6] Group 3: Expert Evaluation and Implications - Academician Fan Daiming of the Chinese Academy of Engineering praised the results, stating that they challenge the traditional view of lifelong medication for T1DM and highlight the potential of HIM as a new clinical treatment paradigm [7] - The global T1DM patient population is approximately 9 million, with traditional treatment costs exceeding RMB 10,000 annually, indicating that HIM could alleviate both financial and health burdens on patients [7]